Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

August 31, 2004

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL

MART-1 antigen

BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

recombinant interleukin-7

Trial Locations (1)

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00091338 - Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter